Sanofi (NASDAQ:SNY) Reaches New 12-Month High – Time to Buy?

Sanofi (NASDAQ:SNY) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $60.12 and last traded at $59.35, with a volume of 3099845 shares changing hands. The stock had previously closed at $59.25.

Analysts Set New Price Targets

SNY has been the topic of a number of research analyst reports. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Stock Down 1.8 %

The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The company has a market cap of $146.41 billion, a price-to-earnings ratio of 23.17, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The stock’s fifty day moving average is $53.27 and its two-hundred day moving average is $52.81.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sanofi

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Invesco Ltd. raised its holdings in shares of Sanofi by 3.5% in the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company’s stock worth $581,619,000 after acquiring an additional 408,752 shares during the last quarter. Bank of America Corp DE increased its stake in Sanofi by 3.8% in the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company’s stock valued at $579,587,000 after buying an additional 441,637 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Sanofi by 88.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock valued at $522,991,000 after buying an additional 5,091,304 shares during the last quarter. Boston Partners increased its stake in Sanofi by 86.4% in the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after buying an additional 2,501,073 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Sanofi by 10.8% in the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company’s stock valued at $182,164,000 after buying an additional 369,530 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.